JP4906717B2 - 遺伝子発現の阻害に関する方法および組成物 - Google Patents

遺伝子発現の阻害に関する方法および組成物 Download PDF

Info

Publication number
JP4906717B2
JP4906717B2 JP2007515472A JP2007515472A JP4906717B2 JP 4906717 B2 JP4906717 B2 JP 4906717B2 JP 2007515472 A JP2007515472 A JP 2007515472A JP 2007515472 A JP2007515472 A JP 2007515472A JP 4906717 B2 JP4906717 B2 JP 4906717B2
Authority
JP
Japan
Prior art keywords
oligonucleotide
gene
cell
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007515472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500838A5 (https=
JP2008500838A (ja
Inventor
ゴーラムレザ・シェイクネージャド
ミナ・ペイテル・スーク
ニール・グッドウィン
デイビッド・オルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sierra Oncology Inc
Original Assignee
ProNAi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProNAi Therapeutics Inc filed Critical ProNAi Therapeutics Inc
Publication of JP2008500838A publication Critical patent/JP2008500838A/ja
Publication of JP2008500838A5 publication Critical patent/JP2008500838A5/ja
Application granted granted Critical
Publication of JP4906717B2 publication Critical patent/JP4906717B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007515472A 2004-06-01 2005-06-01 遺伝子発現の阻害に関する方法および組成物 Expired - Fee Related JP4906717B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US10/858,341 2004-06-01
US10/858,164 2004-06-01
US10/858,013 US20060135455A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,145 2004-06-01
US10/858,146 US20060229267A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,164 US7524827B2 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,094 2004-06-01
US10/858,146 2004-06-01
US10/858,145 US7498315B2 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,094 US20080152700A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,013 2004-06-01
US10/858,341 US20050287667A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US61197404P 2004-09-22 2004-09-22
US60/611,974 2004-09-22
US63721204P 2004-12-17 2004-12-17
US60/637,212 2004-12-17
PCT/US2005/018993 WO2005118824A2 (en) 2004-06-01 2005-06-01 Methods and compositions for the inhibition of gene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011250762A Division JP5922913B2 (ja) 2004-06-01 2011-11-16 遺伝子発現の阻害に関する方法および組成物

Publications (3)

Publication Number Publication Date
JP2008500838A JP2008500838A (ja) 2008-01-17
JP2008500838A5 JP2008500838A5 (https=) 2008-07-17
JP4906717B2 true JP4906717B2 (ja) 2012-03-28

Family

ID=35463455

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007515472A Expired - Fee Related JP4906717B2 (ja) 2004-06-01 2005-06-01 遺伝子発現の阻害に関する方法および組成物
JP2011250762A Expired - Fee Related JP5922913B2 (ja) 2004-06-01 2011-11-16 遺伝子発現の阻害に関する方法および組成物
JP2015023485A Pending JP2015133967A (ja) 2004-06-01 2015-02-09 遺伝子発現の阻害に関する方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011250762A Expired - Fee Related JP5922913B2 (ja) 2004-06-01 2011-11-16 遺伝子発現の阻害に関する方法および組成物
JP2015023485A Pending JP2015133967A (ja) 2004-06-01 2015-02-09 遺伝子発現の阻害に関する方法および組成物

Country Status (10)

Country Link
US (6) US7498315B2 (https=)
EP (2) EP2141173B1 (https=)
JP (3) JP4906717B2 (https=)
CN (1) CN101014608B (https=)
AU (1) AU2005250453B2 (https=)
BR (1) BRPI0511770A (https=)
CA (1) CA2569183A1 (https=)
ES (1) ES2402532T3 (https=)
PL (1) PL2141173T3 (https=)
WO (1) WO2005118824A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519242A (ja) * 2005-12-01 2009-05-14 プロネイ・セラピューティクス・インコーポレイテッド 癌治療法およびそれに用いる医薬組成物
JP2012085642A (ja) * 2004-06-01 2012-05-10 Pronai Therapeutics Inc 遺伝子発現の阻害に関する方法および組成物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3111258B2 (ja) 1991-03-14 2000-11-20 古野電気株式会社 水中探知装置
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
CA2631677C (en) * 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2121925A2 (en) * 2007-03-02 2009-11-25 MDRNA, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
US9023819B2 (en) * 2008-06-09 2015-05-05 National Chung Cheng University Treatment of a disease or a condition associated with aberrant gene hypomethylation by a method involving tailored epigenomic modification
WO2011078301A1 (ja) * 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8597695B1 (en) 2010-11-13 2013-12-03 Sirbal Ltd. Herbal combinations for treatment of a skin condition
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US20170049687A1 (en) 2015-07-29 2017-02-23 Sirbal Ltd. Herbal Combinations For Treating Scalp Conditions
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
WO2013183964A1 (ko) * 2012-06-07 2013-12-12 한양대학교 산학협력단 폐암 진단 및 치료를 위한 표적 단백질
LT4406594T (lt) 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
BR112015010220A2 (pt) 2012-11-05 2017-12-05 Pronai Therapeutics Inc métodos de utilização de biomarcadores para tratamento de câncer
US20160040163A1 (en) * 2013-03-15 2016-02-11 Pronai Therapeutics, Inc. Dnai for the modulation of genes
EP3076984B1 (en) 2013-12-02 2018-11-14 Sirbal Ltd. Herbal combinations for treatment of a skin condition
US10266828B2 (en) 2013-12-16 2019-04-23 Syddansk Universitet RAS exon 2 skipping for cancer treatment
CN105581979A (zh) * 2016-02-24 2016-05-18 南京大学 一种抑制her-2表达的核酸脂质体纳米药物及其制备方法和应用
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
US20210100828A1 (en) * 2017-05-04 2021-04-08 Sanofi Methods for Treatment of Alport Syndrome
JP7427227B2 (ja) * 2020-01-21 2024-02-05 学校法人産業医科大学 腫瘍細胞の生存を低下させるｋｒａｓアンチセンスオリゴヌクレオチド及びその用途
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
WO1992020698A1 (en) * 1991-05-17 1992-11-26 Uab Research Foundation Sequence specific dna binding drugs
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5582986A (en) * 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
US5792608A (en) * 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US6020317A (en) * 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5840497A (en) * 1993-06-11 1998-11-24 The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization Method for specific silencing of genes by DNA methylation
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6365345B1 (en) * 1993-12-23 2002-04-02 Biognostik Gesellscahft Für Biomokekulare Diagnostik mbH Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5518885A (en) * 1994-04-19 1996-05-21 The United States Of America As Represented By The Department Of Health & Human Services ERBB2 promoter binding protein in neoplastic disease
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
WO1996018732A2 (en) 1994-12-15 1996-06-20 Board Of Trustees Of The University Of Illinois Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1997014440A1 (en) 1995-10-19 1997-04-24 Johnson & Johnson Interventional Systems Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
DE19542372A1 (de) 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
WO1997023782A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6291673B1 (en) 1997-10-17 2001-09-18 Purdue Research Foundation Folic acid derivatives
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
MXPA00011312A (es) * 1998-05-20 2003-04-22 Expression Genetics Inc Un vehiculo de gen polimerico de poli-l.lisina injertada con polietilenglicol con porcion de enfoque hepatocitos.
US6429200B1 (en) 1998-07-17 2002-08-06 Mirus Corporation Reverse micelles for delivery of nucleic acids
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US20050176025A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
ITMI20012367A1 (it) * 2001-11-09 2003-05-09 Visufarma S R L Oligonucleotidi antisenso che regolano l'espressione del gene antiapoptotico bcl-2
WO2003099830A2 (en) 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EP1572970A4 (en) * 2002-11-14 2006-11-15 Genta Salus Llc OLIOGONUCLEOTIDES INHIBITORS DIRECTED ON BCL-2
JP2006509010A (ja) 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド アポトーシスの制御
WO2004056971A2 (en) * 2002-12-19 2004-07-08 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
RU2377301C2 (ru) 2003-12-23 2009-12-27 Сантарис Фарма А/С ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
DE102004054730A1 (de) * 2004-03-28 2006-05-11 Novosom Ag Serumstabile amphotere Liposomen
US7498315B2 (en) * 2004-06-01 2009-03-03 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012085642A (ja) * 2004-06-01 2012-05-10 Pronai Therapeutics Inc 遺伝子発現の阻害に関する方法および組成物
JP2009519242A (ja) * 2005-12-01 2009-05-14 プロネイ・セラピューティクス・インコーポレイテッド 癌治療法およびそれに用いる医薬組成物

Also Published As

Publication number Publication date
ES2402532T3 (es) 2013-05-06
EP1773859A4 (en) 2008-03-26
BRPI0511770A (pt) 2008-01-08
HK1107098A1 (en) 2008-03-28
JP2012085642A (ja) 2012-05-10
WO2005118824A3 (en) 2006-11-09
AU2005250453A1 (en) 2005-12-15
EP2141173A1 (en) 2010-01-06
CA2569183A1 (en) 2005-12-15
PL2141173T3 (pl) 2013-08-30
US20080152700A1 (en) 2008-06-26
US7498315B2 (en) 2009-03-03
JP5922913B2 (ja) 2016-05-24
US20060198828A1 (en) 2006-09-07
JP2015133967A (ja) 2015-07-27
WO2005118824A2 (en) 2005-12-15
WO2005118824A8 (en) 2007-01-25
US7524827B2 (en) 2009-04-28
US20060229267A1 (en) 2006-10-12
US20060073596A1 (en) 2006-04-06
CN101014608A (zh) 2007-08-08
EP1773859A2 (en) 2007-04-18
JP2008500838A (ja) 2008-01-17
WO2005118824A9 (en) 2006-06-15
CN101014608B (zh) 2011-07-06
US20060135455A1 (en) 2006-06-22
EP2141173B1 (en) 2013-01-02
US20050287667A1 (en) 2005-12-29
AU2005250453B2 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
JP5922913B2 (ja) 遺伝子発現の阻害に関する方法および組成物
RU2722784C2 (ru) Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
US20250171786A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPa) GENE
US20150374800A1 (en) Inhibitors of Branched-Chain-Aminotransferase-1 (BCAT1) for the Treatment of Brain Tumors
US20210380978A1 (en) The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
EP3722417A1 (en) Cancer spheroid production method and method for selecting colon cancer patients
US9393258B2 (en) Methods and compositions for the inhibition of gene expression
EP2810655A1 (en) Novel antitumor agent and method for screening same
US7807647B2 (en) Methods and compositions for cancer therapy
WO2023086552A2 (en) Lncrna transcripts in melanomagenesis
AU2012202547B2 (en) Methods and compositions for the inhibition of gene expression
HK1107098B (en) Methods and compositions for the inhibition of gene expression
Rojo et al. Demonstration of SLU7 as a new cancer target
AU2015213349A1 (en) Methods and compositions for the inhibition of gene expression
CN121472219A (zh) PKP1 siRNA、抗体、CRISPR-Cas组合物及其应用
KR20220088294A (ko) Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
Brito-Babapulle Genetic Factors Impacting the Biology of B Cell Chronic Lymphocytic Leukemia (B-CLL)-Review

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110524

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120110

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150120

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees